Claudia Ann Christian, a greatly successful American actress, suffered from alcohol addiction for over a decade. She felt that something else was controlling her, as if she was not in the “driver’s seat.”
In 1984, the FDA approved 50 milligrams of Naltrexone as a treatment for heroin addiction.
Later, people discovered that low-dose naltrexone (LDN) can also be used to treat other illnesses.
Due to the pandemic, long COVID and COVID vaccine-related syndromes have become a major health concern in society.
In addition to Ivermectin, research has discovered that low-dose naltrexone might be a good treatment for long COVID and vaccine injuries.
Low-Dose Naltrexone (LDN) Might Treat CancerScientists have found that aside from its original application in treating drug addiction, naltrexone, in small doses, can be used for treating four other common diseases.
1. Treating TumorsIn 1983, Dr. Ian Zagon and Dr. Patricia McLaughlin of Penn State Hershey Medical Center co-authored a paper in Science that first described the significant inhibitory effect of LDN on the growth of neuroblastoma in mice.
The experiments were conducted by subcutaneously injecting naltrexone at 0.1, 1, or 10 mg/kg body weight per day into mice inoculated with neuroblastoma.
The naltrexone low-dose group of 0.1 mg/kg (hollow circles) showed a 36 percent increase in survival time compared to the control group injected with distilled water (x). The naltrexone high-dose group of 10 mg/kg body weight (solid squares) showed a 19 percent decrease in survival.
In addition, there was a 98 percent delay in time to tumor onset in the low-dose naltrexone group.
The data from this experiment suggests that LDN has an inhibitory effect on cancer. The main effect of LDN is through activation of the endogenous opioid receptor system and promoting the release of endorphins.
2. Treating HIV/AIDSDr. Bernard Bihari, a Harvard graduate, and New York physician, began searching for ways to help restore the immune system of people with AIDS after seeing the 1985 epidemic in the United States.
In 1986, his clinical trial at Downstate Medical Center showed that LDN protected AIDS patients by repairing their compromised immune systems.
3. Treating Multiple SclerosisIn 2008, LDN was first used spontaneously (without external intervention) by multiple sclerosis (MS) patients worldwide, with promising results before medical institutions conducted rigorous clinical trials.
It was found that LDN can not only prevent the recurrence of MS but also reduce the progression of the disease.
The data suggest that LDN is a safe, non-toxic, and inexpensive biotherapeutic for MS.
Eighty subjects were enrolled, and 60 subjects completed the trial.
- A 3.3-point improvement on the mental score of Short Form-36 General Health Survey and a 6-point improvement on the Mental Health Inventory.
- A 1.6-point improvement on the Pain Scale, and a 2.4-point improvement on the Perceived Deficits Questionnaire.
4. Treating Irritable Bowel SyndromeAn Israeli study involving 42 patients with irritable bowel syndrome (IBS) was first conducted in 2006.
It was an open-label study that lasted for four weeks and the patients were given 0.5 milligrams of LDN daily.
LDN May Improve Long COVID SymptomsA study was conducted with 52 COVID-19 patients whose median age was 43.5. Forty patients were female. Healthcare workers amounted to 34.8 percent.
The median time from diagnosis of COVID-19 to enrollment was 333 days. Thirty-eight enrollees (73.1 percent) started LDN.
At the end of two months of follow-up, 36 participants(69.2 percent) had completed the survey.
Six of the seven parameters measured had improved, including a significant recovery from long COVID-induced discomforts of daily activities, energy, pain, attention, and sleep disturbances.
There was also a slight improvement in mood.
LDN Helps Fibromyalgia SymptomsOne study found that 30 percent of people who have long COVID suffer from fibromyalgia.
Fibromyalgia is a state of increased microglial cell activity and inflammation in the central nervous system. Once activated, these cells produce pro-inflammatory factors that lead to symptoms such as pain hypersensitivity and fatigue.
LDN is reported to lessen fibromyalgia symptoms.
In addition, the drug improved mechanical and thermal pain thresholds.
Side effects (including insomnia and vivid dreams) were rare and were described as mild.
LDN Helps Chronic Fatigue SyndromeChronic fatigue syndrome is also a common problem with long COVID.
How Does LDN Work?Naltrexone is initially used to treat withdrawal symptoms of opioid and alcohol addiction at doses ranging from 50-200 milligrams/day, as this level of dose completely blocks both endogenous opioids (endorphins, the natural "happy hormones") and exogenous opioids (such as heroin).
Low doses range from 0.5 to 4.5 milligrams/day, equaling 1/10 to 1/100 of the normal dose.
Every drug has two structures called isomers that mirror each other (levorotatory and dextrorotatory), just like the left and right hand of a person. Usually, only one isomer provides a therapeutic effect.
LDN Stimulates Endorphin ProductionStudies have shown that LDN acts on opioid receptors, increasing the level of endogenous opioids and stimulating the production of endorphins.
A 2008 study found that endorphins kept increasing even one month after stopping a dose of less than 5.0 milligrams of LDN.
LDN Modulates the OGFr Axis PathwayOpioid receptors exist in the human body in various subtypes: μ, κ, δ, σ, etc.
One of these subtypes is also known as the Opioid Growth Factor (OGF) receptor, and the OGF/OGF receptor axis pathway is involved in the regulation of tumor growth and proliferation.
When OGF binds to the OGF receptor, cell proliferation will be altered.
In addition, it can also treat autoimmune diseases. These include multiple sclerosis, Crohn's disease, diabetes, and cancer, as well as mental disorders, all of which are associated with dysfunction of the OGF/OGFr axis.
LDN Decreases Pro-inflammatory Cytokines, Increases Anti-Inflammatory FactorsA balanced immune system depends on the body's ability to balance pro-inflammatory and anti-inflammatory factors.
Through multiple means, LDN can decrease pro-inflammatory cytokines, thus reducing inflammation.
A class of proteins called toll-like receptors (TLRs) is part of the immune system. It provides the first line of defense against microbial invasion and has the ability to recognize and activate pathogens and endogenous signaling molecules.
Th1 cytokines tend to respond to viral bacteria. Interferon γ is the main Th1 cytokine. Th2 cytokines including interleukins 4, 5, and 13, are associated with the triggering of allergic and eosinophilic responses.
LDN and Spike Protein InjuriesAt least two-thirds of the world's population has received COVID-19 vaccines, in which spike protein is the main ingredient.
There have been at least 1,200 scientific studies on the cellular, tissue, and organ-level damages brought about by spike proteins.
The most important pathological mechanisms are the following:
Most notably, it involves the brain (brain fog, dementia, mood disorders, psychiatric abnormalities), heart, and endocrine system. These can be life-threatening.
Theoretically speaking, LDN can alleviate systemic inflammatory and neuroinflammatory diseases by inhibiting various inflammatory factors and reducing the body’s reaction to inflammations.
LDN inhibits the activation of microglia in the nervous system and reduces the toxic effects of reactive oxygen species and other potentially neuroexcitatory and neurotoxic chemical production. Thus, it can protect the brain and nerve cells.
LDN’s Multiple Treatment Potential Brings HopeOnce the body's natural self-regulatory mechanisms are disrupted by external drugs, viruses, and toxins, disorders may occur, such as addiction, COVID-19, or COVID vaccine injury.
In addition to forcibly blocking external stimuli (for example, the addictive drugs), the most fundamental treatment requires the body's natural mechanisms to return to normal.
The idea of medical treatment is mainly to suppress symptoms, it is a reactive action but not a proactive measurement. This approach equates one disease to one target, and pairs it with one drug.
The fact that low-dose naltrexone, a drug originally used to treat drug addiction can actually treat other chronic illnesses suggests that the human body is a complex, multidimensional system that to date is still poorly understood.
Little is known about the interconnectedness of the brain, the immune system, and the various organs of the body.
Yet, many traditional therapies or natural therapies are able to heal the whole body at a deeper, microscopic level.
The subtleties of the human body still need to be explored with open-mindedness, so as to better understand it. Only when we are able to do this in a humble way will we be able to find a holistic way to achieve ultimate health.